What question did this study set out to answer?

This research aims to evaluate the effects of switching from branded to generic pirfenidone on lung function and tolerability in patients with idiopathic pulmonary fibrosis.

April 19, 2026Open Access

Efficacy and tolerability of generic pirfenidone after switch from Esbriet® in idiopathic pulmonary fibrosis: a real-world observational study

RTRoberto TonelliUniversity of Modena and Reggio Emilia MTMaria Giulia TurchianoSanta Maria Nuova Hospital AMAntonio MorettiUniversity of Modena and Reggio Emilia

Key Points

This research aims to evaluate the effects of switching from branded to generic pirfenidone on lung function and tolerability in patients with idiopathic pulmonary fibrosis.
Real-world cohort study design
Involvement of patients with idiopathic pulmonary fibrosis
Comparison of lung function decline and treatment tolerability pre- and post-switch
No clinically meaningful differences in lung function decline after switching
Treatment tolerability remained comparable between branded and generic pirfenidone

Abstract

In this real-world cohort of patients with IPF, switching from branded to generic pirfenidone was not associated with clinically meaningful differences in lung function decline or treatment tolerability.

AI से पूछें

Bookmark

View Full Paper